testing / Shutterstock.com

15 February 2024Big PharmaMarisa Woutersen

MSD can appeal SPC ruling due to 'wrongly decided' case

Judge says UK courts should depart from a European precedent following Brexit | MSD counsel says appeal had been granted due to courts' “flip-flopping” on the precedent(s) set by the landmark cases Neurim and Santen.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

MSD, Pfizer try to stop three Steglatro generics

29 March 2022 Merck Sharp & Dohme and Pfizer have filed three complaints with the Delaware district court to attempt to shut down proposed generics of Steglatro—a diabetes treatment that Pfizer licences to MSD.

AstraZeneca, MSD sue MSN and Sandoz over Calquence generics

8 February 2022 AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.

More on this story

MSD, Pfizer try to stop three Steglatro generics

29 March 2022 Merck Sharp & Dohme and Pfizer have filed three complaints with the Delaware district court to attempt to shut down proposed generics of Steglatro—a diabetes treatment that Pfizer licences to MSD.

AstraZeneca, MSD sue MSN and Sandoz over Calquence generics

8 February 2022 AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.

More on this story

MSD, Pfizer try to stop three Steglatro generics

29 March 2022 Merck Sharp & Dohme and Pfizer have filed three complaints with the Delaware district court to attempt to shut down proposed generics of Steglatro—a diabetes treatment that Pfizer licences to MSD.

AstraZeneca, MSD sue MSN and Sandoz over Calquence generics

8 February 2022 AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.

More features

Fed Circ: Generic doesn’t infringe Metacel MS drug

WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025

Strategic IP protection for biotech-related GenAI

South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug

Patent litigator with biotech and medical device background joins Sterlington

Resilience and the power of brands: Elisabeth Stewart Bradley on 9/11, inclusion and the INTA presidency

Fenwick establishes new Boston office with trio of IP partners from Cooley

How pharma should prep for the six-bill avalanche from Congress